Skip to main content

A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients with Mild to Moderate Parkinson’s Disease on Stable Symptomatic Parkinson’s Disease Medication

Open
  • Protocol code: BAN0805-201
  • EudraCT code: No aplica
  • Research group: Neurodegenerative Diseases
  • Service: Neurology
  • Principal investigator:  Hernández Vara, Jorge
  • Pathology: Malalties del sistema nerviós
  • Phase: Fase II